Status:
COMPLETED
Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Renal Insufficiency
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and ...
Eligibility Criteria
Inclusion
- Complete the core study
Exclusion
- Did not comply with core study requirements
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
349 Patients enrolled
Trial Details
Trial ID
NCT00765830
Start Date
September 1 2008
End Date
April 1 2011
Last Update
December 17 2020
Active Locations (90)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinica de Fracturas y Ortopedia
Buenos Aires, Argentina
2
Hospital Teodoro Alvarez
Buenos Aires, Argentina
3
Instituto de Investigaciones Clinicas de Mar del Plata
Buenos Aires, Argentina
4
Instituto Medico Especializado IME
Buenos Aires, Argentina